- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04411446
Cholecalciferol to Improve the Outcomes of COVID-19 Patients (CARED)
Randomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 Patients
The recent inception of the coronavirus SARS-CoV-2, responsible for the coronavirus disease (COVID-19), has caused thousands of deaths globally. The most frequently reported complications among COVID-19 patients are from respiratory involvement.
Vitamin D has immunomodulatory effects that could protect against COVID-19 infection. Indeed, there is good evidence from randomized clinical trials suggesting that high doses of vitamin D administered during cold seasons prevent viral respiratory infections in at risk individual, and more recently, observational studies suggested that the mortality rate from COVID-19 is inversely correlated with levels of serum 25(OH)vitamin D.
The hypothesis of the study is that a high dose of vitamin D given orally to patients admitted to the hospital for COVID-19 will prevent the occurrence of respiratory deragement and other adverse clinical events.
To evaluate the aforementioned hypothesis, a randomized, controlled, double-blind, clinical trial comparing a 500.000 UI dose of vitamin D versus placebo among COVID-19 patients at moderate risk, requiring hospitalization but without requirements of critical care at admission was designed. The intervention will be one dose of 500.000 UI given orally or matching placebo.
The trial has a sequential design with two steps:
- The first step, projected to include 200 patients, will assess the effects of the intervention on the respiratory SOFA; and
- If there is a detectable effects, the second step, projected to include 1264 patients, will assess the effects on a combined event that includes need of high dose of oxygen or mechanical ventilation.
All study outcomes will be measured during the index hospitalization.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Buenos Aires
-
Florencio Varela, Buenos Aires, Argentina, 1888
- Hospital De Alta Complejidad en Red El Cruce
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- SARS-CoV-2 confirmed infection;
- Admission to a hospital;
- Expected hospitalization in the center for at least for 24 hs;
- Oxygen Saturation >90% breathing without oxygen supplement;
- Age at least 45 years or the presence of one of the followings risk factors:
- Hypertension;
- Diabetes (type I o II);
- At least moderate COPD or Asthma;
- Cardiovascular disease (history of myocardial infarction, coronary angioplasty, coronary artery bypass grafting or valve replacement surgery);
- Body Mass Index >=30;
- Signed Written consent.
Exclusion Criteria:
- <18 years old;
- Women in childbearing age;
- >= 72 hs since current admission;
- Requirement for high dose of oxygen (>5 liters/minute) or mechanical ventilation (non-invasive or invasive);
- History of Chronic kidney disease requiring hemodialysis or chronic liver failure;
- Inability for oral intake;
- Previous treatment with pharmacological vitamin D;
- History of:
- previous treatment with anticonvulsants;
- sarcoidosis;
- malabsorption syndrome;
- Known hypercalcemia.
- Life expectancy less than 6 months;
- Known allergy to the study medication;
- Any condition impeding to bring informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vitamin D
5 capsules containing 100.000 UI of vitamin D each.
The intervention will be 5 capsules given in one-time oral intake.
|
5 capsules of 100.000
UI Vitamin D orally given all at once.
One dose.
Other Names:
|
Placebo Comparator: Placebo
5 capsules containing placebo.
The intervention will be 5 capsules given in one-time oral intake.
|
5 capsules of containing placebo orally given all at once.
One dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Respiratory SOFA.
Time Frame: One week
|
Is the respiratory component of the sequential organ failure assessment score (SOFA score). It is a 4 points scale, each point indicate a deeper respiratory impairment. The score is based on the relationship between the arterial pressure of oxygen (PaO2) and inspired fraction of oxygen (FiO2), as the ratio of both (PaFi). In the cases were arterial blood gas are not measured, the pulse oximetry will be used instead. The respiratory SOFA is as follows:
The minimum respiratory SOFA score will be record on daily basis during first week or to death or discharge, whichever occur first. This outcome is the primary outcome of the first study phase. |
One week
|
Need of a high dose of oxygen or mechanical ventilation.
Time Frame: 30 days
|
The start of oxygen supplementation at FiO2 >40% or the initiation of invasive through orotracheal intubation) or non-invasive ventilation (Continuous positive airway pressure or Bilevel positive airway ventilation). This outcome will be recorded during hospitalization to 30 days, the death or discharge, whichever occur first. This is the primary outcome of the second study phase. |
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in oxygen saturation.
Time Frame: One week
|
Difference between the oxygen saturation at study entry and the lowest oxygen saturation measured during the first week, the death or discharge, whichever occur first. The oxygen saturation will be measured by pulse oximetry using commercially available devices. |
One week
|
Oxygen desaturation.
Time Frame: One week
|
Oxygen saturation equal or less than 90% in any moment during the hospitalization. This outcome will be measured by pulse oximetry using commercially available devices. The outcome will be measured during the first week, the death or hospital discharge, whichever occur first. |
One week
|
Change in Quick SOFA score.
Time Frame: 30 days.
|
The difference between the Quick SOFA score at study entry and the highest value recorded during the hospitalization. The outcome will be measured during the hospitalization until 30 days, the death or discharge whichever occur first. |
30 days.
|
Myocardial infarction.
Time Frame: 30 days
|
Myocardial infarction is defined as suspicious symptoms with new Q waves in the EKG and enzymatic elevations compatible with the Fourth MI Definition. The outcome will be measured during the hospitalization until 30 days, the death or discharge whichever occur first. |
30 days
|
Stroke.
Time Frame: 30 days
|
Stroke is defined as a focal neurological loss lasting >24 hs as reported by treating physician. The outcome will be measured during the hospitalization until 30 days, the death or discharge whichever occur first. |
30 days
|
Acute kidney injury.
Time Frame: 30 days
|
Acute kidney injury is defined as an increase of at least 50% in serum creatinine levels (as compared with any previous value during the hospitalization). The outcome will be measured during the hospitalization until 30 days, the death or discharge whichever occur first. |
30 days
|
Pulmonary thromboembolism.
Time Frame: 30 days
|
Pulmonary thromboembolism is defined as the presence of suspicious symptoms (i.e. dyspnea) confirmed with objective evidence of a thrombus in the pulmonary tree by CT or MRI or Pulmonary Angiography. The outcome will be measured during the hospitalization until 30 days, the death or discharge whichever occur first. |
30 days
|
Combined endpoint (stroke, myocardial infarction, acute kidney injury and pulmonary thromboembolism.
Time Frame: 30 days
|
Combined outcome of the aforementioned events, Stroke is defined as a focal neurological loss lasting >24 hs as reported by treating physician. Myocardial infarction is defined as suspicious symptoms with new Q waves in the EKG and enzymatic elevations compatible with the Fourth MI Definition. Pulmonary thromboembolism is defined as the presence of suspicious symptoms (i.e. dyspnea) confirmed with objective evidence of a thrombus in the pulmonary tree by CT or MRI or Pulmonary Angiography. Acute kidney injury is defined as an increase of at least 50% in serum creatinine levels (as compared with any previous value during the hospitalization). The outcome will be measured during the hospitalization until 30 days, the death or discharge whichever occur first. |
30 days
|
Admission to ICU.
Time Frame: 30 days
|
Admission to Intensive Care Unit due to clinical deterioration as judged by the treating physician. The outcome will be measured during the hospitalization until 30 days, the death or discharge whichever occur first. |
30 days
|
Invasive Mechanical Ventilation.
Time Frame: 30 days
|
The start of mechanical ventilation invasive during the hospitalization until 30 days, the death or discharge whichever occur first.
|
30 days
|
Hospital Length of Stay.
Time Frame: 30 days.
|
Total duration of initial hospital stay in days. The outcome will be measured during the hospitalization until 30 days, the death or discharge whichever occur first. In the cases with hospital stays longer than 30 days, it will considered as 30 days. |
30 days.
|
ICU length of stay.
Time Frame: 30 days
|
Total duration of initial ICU stay in days. The outcome will be measured during the hospitalization until 30 days, the death or discharge whichever occur first. In the cases with ICU stays longer than 30 days, it will considered as 30 days. |
30 days
|
Death
Time Frame: 30 days.
|
Death of any cause during the hospitalization until 30 days or discharge whichever occur first.
|
30 days.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Walter Manucha, PhD, IMBECU, Univ Nac de Cuyo, Mendoza, Argentina
- Principal Investigator: Carlos Tajer, MD, Hospital de Alta Complejidad El Cruce - Universidad Nacional Arturo Jauretche
- Principal Investigator: Laura Antonietti, MD, Hospital de Alta Complejidad El Cruce - Universidad Nacional Arturo Jauretche
- Principal Investigator: León Ferder, MD, Maimonides University
- Principal Investigator: Felipe Inserra, MD, Universidad Maimónides - Hospital Universitario Austral
- Principal Investigator: Javier Mariani, MD, Hospital de Alta Complejidad El Cruce - Universidad Nacional Arturo Jauretche
Publications and helpful links
General Publications
- Martin Gimenez VM, Inserra F, Tajer CD, Mariani J, Ferder L, Reiter RJ, Manucha W. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment. Life Sci. 2020 Aug 1;254:117808. doi: 10.1016/j.lfs.2020.117808. Epub 2020 May 15.
- Mariani J, Antonietti L, Tajer C, Ferder L, Inserra F, Sanchez Cunto M, Brosio D, Ross F, Zylberman M, Lopez DE, Luna Hisano C, Maristany Batisda S, Pace G, Salvatore A, Hogrefe JF, Turela M, Gaido A, Rodera B, Banega E, Iglesias ME, Rzepeski M, Gomez Portillo JM, Bertelli M, Vilela A, Heffner L, Annetta VL, Moracho L, Carmona M, Melito G, Martinez MJ, Luna G, Vensentini N, Manucha W. High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: Multicentre randomized controlled clinical trial. PLoS One. 2022 May 27;17(5):e0267918. doi: 10.1371/journal.pone.0267918. eCollection 2022.
- Mariani J, Tajer C, Antonietti L, Inserra F, Ferder L, Manucha W. High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial (CARED-TRIAL). Trials. 2021 Feb 1;22(1):111. doi: 10.1186/s13063-021-05073-3.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 001 (NavyGHB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID
-
European Institute of OncologyFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; Azienda Ospedaliera... and other collaboratorsCompleted
-
Owlstone LtdCambridge University Hospitals NHS Foundation TrustCompleted
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Sultan Qaboos UniversityCompletedCOVID-19 | Non-CovidOman
-
Assiut UniversityRecruiting
-
Jilin UniversityUnknown
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Miami VA Healthcare SystemNot yet recruiting
Clinical Trials on Vitamin D
-
PfizerTerminated
-
Umeå UniversityRegion SkaneCompleted
-
Fundación Cardiovascular de ColombiaUniversidad Industrial de Santander; Farma de Colombia SACompletedVitamin D Deficiency | Overweight and Obesity | Overweight AdolescentsColombia
-
Khon Kaen UniversityNot yet recruiting
-
Nutrition Institute, SloveniaSlovenian Research Agency; Higher School of Applied Sciences (VIST); Valens Int...CompletedVitamin D DeficiencySlovenia
-
USDA, Western Human Nutrition Research CenterCompletedVitamin D DeficiencyUnited States
-
University of AarhusNot yet recruitingImmune System Diseases | Growth | Child Development | Vitamin D Supplementation
-
University Hospital, Basel, SwitzerlandCompleted
-
Cornell UniversityArogyavaram Medical CentreNot yet recruiting
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting